National Laboratory Astana, Nazarbayev University, Kabanbai Batyr Ave. 53, Astan Z05H0P9, Kazakhstan.
National Center for Biotechnology, 13/5 Kurgalzhynskoe Road, Astana Z05K8D5, Kazakhstan.
Molecules. 2024 Jul 31;29(15):3627. doi: 10.3390/molecules29153627.
Reactions with allyl-, acetyl-, and phenylisothiocyanate have been studied on the basis of 3-amino-4,6-dimethylpyridine-2(1)-one, 3-amino-4-phenylpyridine-2-one, and 3-amino-4-(thiophene-2-yl)pyridine-2(1)-one (benzoyl-)isothiocyanates, and the corresponding thioureide derivatives were obtained. Twelve thiourea derivatives were obtained and studied for their anti-diabetic activity against the enzyme α-glucosidase in comparison with the standard drug acarbose. The comparison drug acarbose inhibits the activity of α-glucosidase at a concentration of 15 mM by 46.1% (IC for acarbose is 11.96 mM). According to the results of the conducted studies, it was shown that alkyl and phenyl thiourea derivatives , in contrast to their acetyl-(benzoyl) derivatives and , show high antidiabetic activity. Thus, 1-(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)-3-phenylthiourea has the highest inhibitory activity against the enzyme α-glucosidase, exceeding the activity of the comparison drug acarbose, which inhibits the activity of α-glucosidase by 56.6% at a concentration of 15 mm (IC = 9,77 mM). 1-(6-methyl-2-oxo 4-(thiophen-2-yl)-1,2-dihydropyridin-3-yl)-3-phenylthiourea has inhibitory activity against the enzyme α-glucosidase, comparable to the comparison drug acarbose, inhibiting the activity of α-glucosidase at a concentration of 15 mm per 41.2% (IC = 12,94 mM). Compounds and showed inhibitory activity against the enzyme α-glucosidase, with a lower activity compared to acarbose, inhibiting the activity of α-glucosidase at a concentration of 15 mM by 23.3%, 26.9%, and 35.2%, respectively. The IC against α-glucosidase for compounds , , and was found to be 16.64 mM, 19.79 mM, and 21.79 mM, respectively. The other compounds , and did not show inhibitory activity against α-glucosidase. Thus, the newly synthesized derivatives of thiourea based on 3-aminopyridine-2(1)-ones are promising candidates for the further modification and study of their potential anti-diabetic activity. These positive bioanalytical results will stimulate further in-depth studies, including in vivo models.
基于 3-氨基-4,6-二甲基-2(1H)-吡啶酮、3-氨基-4-苯基-2(1H)-吡啶酮和 3-氨基-4-(噻吩-2-基)-2(1H)-吡啶酮(苯甲酰基)异硫氰酸酯,研究了烯丙基、乙酰基和苯基异硫氰酸酯的反应,并获得了相应的硫脲衍生物。合成了 12 种硫脲衍生物,并将其与标准药物阿卡波糖进行比较,研究了它们对α-葡萄糖苷酶的抗糖尿病活性。比较药物阿卡波糖在 15mM 浓度下抑制α-葡萄糖苷酶活性 46.1%(阿卡波糖的 IC 为 11.96mM)。根据进行的研究结果表明,与它们的乙酰基(苯甲酰基)衍生物相比,烷基和苯基硫脲衍生物表现出高的抗糖尿病活性。因此,1-(4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)-3-苯基硫脲对酶α-葡萄糖苷酶具有最高的抑制活性,超过了比较药物阿卡波糖的活性,在 15mm 浓度下抑制α-葡萄糖苷酶活性 56.6%(IC=9.77mM)。1-(6-甲基-2-氧代-4-(噻吩-2-基)-1,2-二氢吡啶-3-基)-3-苯基硫脲对酶α-葡萄糖苷酶具有抑制活性,与比较药物阿卡波糖相当,在 15mm 浓度下抑制α-葡萄糖苷酶活性 41.2%(IC=12.94mM)。化合物和对酶α-葡萄糖苷酶具有抑制活性,其活性低于阿卡波糖,在 15mM 浓度下分别抑制α-葡萄糖苷酶活性 23.3%、26.9%和 35.2%。化合物、和对α-葡萄糖苷酶的 IC 值分别为 16.64mM、19.79mM 和 21.79mM。其他化合物和对α-葡萄糖苷酶没有抑制活性。因此,基于 3-氨基吡啶-2(1)-酮的新合成硫脲衍生物是进一步修饰和研究其潜在抗糖尿病活性的有前途的候选物。这些积极的生物分析结果将刺激进一步的深入研究,包括体内模型。